Skip to main content
Healthcare

STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more

STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more

Feed excerpt — reported by STAT News

Novartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deaths

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.